Clinical Trial: Phase II Pediatric Study With Dabrafenib in HGG Patients

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional




Official Title: Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib Treatment in Children and Adolescent Patients With BRAF V600 Mutation Positive Relapsed or Refractory High Grade Glioma (HGG)

Brief Summary: The purpose of this study is to investigate the activity of dabrafenib in children and adolescent patients with BRAF V600 mutation positive relapsed or refractory high grade glioma.